Cell Therapeutics, Inc. (CTIC) Sets Major Goals for 2009; Reviews 2008 Accomplishments
Cell Therapeutics, Inc. recently reviewed its 2008 accomplishments and 2009 targeted milestones in meetings held with the JP Morgan Healthcare Conference in San Francisco. Today the company shared the details of those meetings with the investment community. "With a focus on cutting-edge oncology drug products, CTI aims to complete its transition from a research-based organization to a leading commercial oncology company," stated James A. Bianco, M.D., CEO of Cell Therapeutics. "In 2008 we set the stage for becoming a multi-product commercial oncology operating company, with Zevalin currently under priority review by the FDA in the U.S. for label expansion, OPAXIO(TM) under…